Business Context and Reporting Period
This Form 8-K is filed by Palatin Technologies, Inc. (Palatin) on November 5, 2025. The filing addresses the Company's entry into a material underwriting agreement and its efforts to regain compliance with NYSE American listing standards following a suspension of trading on May 7, 2025, due to low stock price. The Company's stock currently trades on the OTCQB Market under the symbol "PTNT" and is expected to resume trading on the NYSE American under the symbol "PTN" on November 12, 2025.
Key Financial Metrics and Capital Structure
- Offering Details: Public offering of 2,430,769 shares of common stock (or pre-funded warrants) plus Series J and Series K warrants.
- Offering Price: $6.50 per share of common stock and accompanying warrants.
- Gross Proceeds: Approximately $15.8 million.
- Net Proceeds: Expected to be $14.7 million after underwriting discounts and expenses.
- Over-Allotment Option: Underwriters granted a 45-day option to purchase up to 364,615 additional shares.
- Recent Revenue: $8.8 million recognized in the quarter ended September 30, 2025, from a business development collaboration with Boehringer Ingelheim International GmbH.
- Stockholders' Equity: Pro-forma equity is projected to exceed the $6.0 million threshold required for NYSE American listing.
Material Changes and Listing Compliance
The Company implemented a one-for-fifty reverse stock split effective August 11, 2025, to address low stock price concerns. The primary material change reported is the significant increase in stockholders' equity driven by the $8.8 million collaboration revenue and the anticipated $15.8 million equity offering. These actions are intended to satisfy the NYSE American "Stockholders' Equity Rule" (Section 1003(a)(iii)), which requires equity greater than $6.0 million. The filing states that the closing of the offering will result in regained compliance with all applicable listing requirements.
Guidance, Outlook, and Warrant Terms
Warrant Structure:
- Series J Warrants: Exercise price of $6.50; immediately exercisable. Expire on the earlier of 18 months from issuance or 31 days after FDA acceptance of an Investigational New Drug (IND) for an in-house obesity treatment compound.
- Series K Warrants: Exercise price of $8.125; immediately exercisable. Expire on the five-year anniversary, unless terminated earlier if Series J warrants are not terminated prior to the expiration of the FDA Exercise Period.
Outlook and Risks: The Company expects the offering to close on or about November 12, 2025, contingent on the resumption of trading on the NYSE American. The filing includes standard forward-looking statements regarding the reinstatement of trading and future performance, noting that actual results may differ due to risks and uncertainties. No specific financial guidance for future periods beyond the offering proceeds is provided.
Investor Verification Checklist
- Confirm the actual closing date of the offering and the final net proceeds received.
- Verify the resumption of trading on the NYSE American under symbol "PTN" on November 12, 2025.
- Monitor the status of the FDA acceptance of the Investigational New Drug for the obesity treatment compound, as this triggers the expiration of Series J Warrants.
- Review the full text of the Underwriting Agreement and warrant forms (Exhibits 1.1, 4.1, 4.2, 4.3) for detailed terms and conditions.
- Assess the impact of the one-for-fifty reverse stock split on historical financial data and share ownership.